Observational studyPediatric research2026
Bilirubin-albumin molar ratio for screening high unbound bilirubin across gestational ages.
Observational study in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Single Cutoffs: Gestational and Postnatal Age-Specific Interpretation of Neonatal Laboratory Markers.Pediatrics international : official journal of the Japan Pediatric SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2022 AAP Guideline recommends using the bilirubin-albumin molar ratio (BAMR) as an index of unbound bilirubin (UB) levels in term newborns. This study evaluated whether BAMR can reliably screen elevated UB levels across newborns of various gestational ages (GAs) during the first two weeks of life.
methodsThis retrospective observational study included newborns delivered between 2022 and 2023, categorized into four groups by GA: 22-27, 28-31, 32-36, and ≥37 weeks. Correlations between BAMRs and UB levels were analyzed. Estimated UB from BAMRs was compared with measured UB using Bland-Altman plots. Receiver operating characteristic (ROC) curves identified BAMR thresholds for UB ≥ 0.8 μg/dL.
resultsBAMRs correlated significantly with UB across all groups (Rrm = 0.823-0.891). Bland-Altman analyses showed 95% limits of agreement of approximately -0.25 to 0.25 μg/dL. BAMR thresholds identifying UB ≥ 0.8 μg/dL were 0.35-0.47, with areas under ROC curves of 0.880-0.982.
conclusionIn early postnatal period, BAMR shows strong correlations with UB levels across GA groups, including preterm newborns. Although it does not allow precise UB quantification, BAMR may serve as a screening tool to identify newborns with high UB who are at risk of bilirubin neurotoxicity. IMPACT STATEMENT: Bilirubin-albumin molar ratio (BAMR) strongly correlates with unbound bilirubin (UB) levels across all gestational ages, including in preterm newborns. BAMR is inaccurate to quantify the UB level, but it may provide an estimate. While BAMR may serve as a screening tool, it should never be used as a stand-alone diagnostic method. These findings support broader clinical use of BAMR and may inform future guidelines for neonatal hyperbilirubinemia across all gestational ages.
Indexed as
Identifiers
41429955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.